<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742013</url>
  </required_header>
  <id_info>
    <org_study_id>Laennec-IIT</org_study_id>
    <nct_id>NCT01742013</nct_id>
  </id_info>
  <brief_title>Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients</brief_title>
  <official_title>Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ho Cheol Shin, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GCJBP Laennec Injection contains a variety of cytokines derived from human placenta, amino
      acids, peptides, nucleobases, and carbohydrates. This product is approved for improving liver
      function. Also, it has been prescribed for lots of diseases such as menopausal disorders,
      atopic dermatitis, skin cares as well as fatigue for long time. Although its action mechanism
      and clinical effectiveness are not still clear, there are reports which say a strong
      probability of its clinical effectiveness in the chronic fatigue patients.

      This study aims to investigate the safety and efficacy of GCJBP Laennec Inj. (Human placenta
      hydrolysate) in the chronic fatigue patients through a randomized controlled tial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Fatigue Severity Scale (FSS)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change per item of Fatigue Severity Scale (FSS)</measure>
    <time_frame>Baseline, 3, 6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients whose FSS decreased from 4 and more to less than 4</measure>
    <time_frame>Baseline, 3, 6 and 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline, 3 and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Multidimensional Fatigue Inventory (MFI)</measure>
    <time_frame>Baseline, 3 and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Improvement Scale (GIS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>GIS assessment after 6-week study treatment by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the concentration of salivary cortisol</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the concentration of interleukin-6 and interleukin 1b</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV) parameters at resting</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compliance rate of used study drugs to prescribed study drugs after 6-week treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>9 weeks</time_frame>
    <description>All adverse events reported for study duration of 9 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Idiopathic Chronic Fatigue</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GCJBP Laennec Inj.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCJBP Laennec Inj.</intervention_name>
    <description>Test drug</description>
    <arm_group_label>GCJBP Laennec Inj.</arm_group_label>
    <other_name>Human placenta hydrolysate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline solution (NaCl 0.9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with chronic fatigue syndrome or idiopathic chronic fatigue

          -  Given written informed consent

          -  Male or female aged between 20 and 65

          -  Patient who can read and answer to written questionnaires

          -  Patient who agrees to visit clinic for study drug injection 3 times per a week for 6
             weeks

        Exclusion Criteria:

          -  Patient who has been administrated with any other investigational product for 28 days
             prior to screening visit

          -  Patient who is pregnant or childbearing potential female patient who does not consent
             for contraception during the study

          -  Patient who has a hypersensitivity provoked by study drug or others drived from
             animals

          -  Patient who has been received with any human placenta product for 6 months before
             study participation

          -  Abnormal liver function

          -  Abnormal renal function

          -  Back Depression Inventory (BDI) II is more than 29

          -  Underlying disease/conditions, in the investigator's judgment, which will be unable to
             participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Cheol Shin, M.D., Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Ho Cheol Shin, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Fatigue</keyword>
  <keyword>CFS</keyword>
  <keyword>ICF</keyword>
  <keyword>human placenta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

